| Aceclofenac | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | |
| Aceclofenac | hsa00480 | Glutathione metabolism | 3.29E-04 | 4 | Q9UJ14, Q16772, P09211, P30041 | GGTL3, GSTA3, GSTP1, PRDX6 | More | |
| Aceclofenac | hsa00500 | Starch and sucrose metabolism | 1.79E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | |
| Aceclofenac | hsa00510 | N-Glycan biosynthesis | 1.00E-02 | 2 | O94777, Q9BVK2 | DPM2, ALG8 | More | |
| Aceclofenac | hsa00561 | Glycerolipid metabolism | 3.09E-02 | 2 | P14550, Q86XP1 | AKR1A1, DGKH | More | |
| Aceclofenac | hsa00563 | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 3.47E-03 | 2 | O94777, Q14442 | DPM2, PIGH | More | |
| Aceclofenac | hsa00565 | Ether lipid metabolism | 1.61E-04 | 2 | Q9Y6K0, Q8N661 | CEPT1, TMEM86B | More | |
| Aceclofenac | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | |
| Aceclofenac | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | |
| Aceclofenac | hsa00600 | Sphingolipid metabolism | 4.47E-02 | 2 | Q96G23, Q86VZ5 | LASS2, SGMS1 | More | |
| Aceclofenac | hsa00730 | Thiamine metabolism | 4.66E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | |
| Aceclofenac | hsa00770 | Pantothenate and CoA biosynthesis | 7.90E-03 | 3 | O95498, O95497, Q9NRN7 | VNN2, VNN1, AASDHPPT | More | |
| Aceclofenac | hsa00970 | Aminoacyl-tRNA biosynthesis | 7.90E-03 | 3 | O95363, P54136, Q15046 | FARS2, RARS1, KARS | More | |
| Aceclofenac | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-05 | 4 | Q16772, P78417, P09211, P11712 | GSTA3, GSTO1, GSTP1, CYP2C9 | More | |
| Aceclofenac | hsa00982 | Drug metabolism - cytochrome P450 | 1.77E-04 | 4 | P11712, Q16772, P09211, P78417 | CYP2C9, GSTA3, GSTP1, GSTO1 | More | |
| Aceclofenac | hsa00983 | Drug metabolism - other enzymes | 1.92E-03 | 5 | P04183, P32320, P05164, Q16772, P09211 | TK1, CDA, MPO, GSTA3, GSTP1 | More | |
| Aceclofenac | hsa01100 | Metabolic pathways | 2.14E-05 | 24 | Q9Y234, P35790, Q16772, P09211, Q9UJ14, P30041, Q6ZQY3, P20839, P40926, O94777, Q7KZN9, Q9Y6K0, P15121, Q86XP1, P14550, Q9UHK6, Q86VZ5, Q96G23, Q9BVK2, Q14442, Q9BQB6, Q06055, Q99437, Q9NVH6 | LIPT1, CHKA, GSTA3, GSTP1, GGTL3, PRDX6, GADL1, IMPDH1, MDH2, DPM2, COX15, CEPT1, AKR1B1, DGKH, AKR1A1, AMACR, SGMS1, LASS2, ALG8, PIGH, VKORC1, ATP5G2, ATP6V0B, TMLHE | More | |
| Aceclofenac | hsa01524 | Platinum drug resistance | 4.44E-02 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | |
| Aceclofenac | hsa02010 | ABC transporters | 4.93E-02 | 1 | Q8IZY2 | ABCA7 | More | |
| Aceclofenac | hsa03010 | Ribosome | 1.88E-02 | 6 | P62753, P25398, P32969, P62829, P18077, P36578 | RPS6, RPS12, RPL9, RPL23, RPL35A, RPL4 | More | |
| Aceclofenac | hsa03020 | RNA polymerase | 3.59E-02 | 2 | P30876, P62487 | POLR2B, POLR2G | More | |
| Aceclofenac | hsa04062 | Chemokine signaling pathway | 3.93E-03 | 10 | P25024, P25025, P47992, Q9UBD3, P07948, P63218, P50151, P49407, Q08881, P49841 | CXCR1, CXCR2, XCL1, XCL2, LYN, GNG5, GNG10, ARRB1, ITK, GSK3B | More | |
| Aceclofenac | hsa04064 | NF-kappa B signaling pathway | 2.30E-04 | 8 | P10415, O00463, Q04759, Q9UDY8, Q16548, Q13315, P24522, P09341 | BCL2, TRAF5, PRKCQ, MALT1, BCL2A1, ATM, GADD45A, CXCL1 | More | |
| Aceclofenac | hsa04071 | Sphingolipid signaling pathway | 1.00E-03 | 5 | P21453, Q9H228, Q13362, Q9BX95, P10415 | S1PR1, EDG8, PPP2R5C, SGPP1, BCL2 | More | |
| Aceclofenac | hsa04080 | Neuroactive ligand-receptor interaction | 1.05E-03 | 8 | P08311, Q15722, P21453, Q9H228, O00398, P21730, Q16581, P07550 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, C5AR1, C3AR1, ADRB2 | More | |
| Aceclofenac | hsa04115 | p53 signaling pathway | 3.98E-02 | 5 | P24522, Q13315, Q53FA7, O95067, P10415 | GADD45A, ATM, TP53I3, CCNB2, BCL2 | More | |
| Aceclofenac | hsa04140 | Autophagy - animal | 3.19E-02 | 4 | P22694, Q14643, P10415, Q04759 | PRKACB, ITPR1, BCL2, PRKCQ | More | |
| Aceclofenac | hsa04141 | Protein processing in endoplasmic reticulum | 4.88E-02 | 4 | P18848, O60337, P11142, P07900 | ATF4, MARH6, HSPA8, HSP90AA1 | More | |
| Aceclofenac | hsa04145 | Phagosome | 4.48E-02 | 5 | Q15080, P05164, O60603, P35443, P13765 | NCF4, MPO, TLR2, THBS4, HLA-DOB | More | |
| Aceclofenac | hsa04210 | Apoptosis | 3.83E-03 | 8 | Q13315, P10415, O76075, P24522, Q16548, P43234, P18848, Q14643 | ATM, BCL2, DFFB, GADD45A, BCL2A1, CTSO, ATF4, ITPR1 | More | |
| Aceclofenac | hsa04217 | Necroptosis | 4.42E-04 | 6 | P07900, P15104, P05141, P01584, P0C0S5, Q13557 | HSP90AA1, GLUL, SLC25A5, IL1B, H2AFZ, CAMK2D | More | |
| Aceclofenac | hsa04330 | Notch signaling pathway | 3.09E-02 | 2 | P49768, P78504 | PSEN1, JAG1 | More | |
| Aceclofenac | hsa04340 | Hedgehog signaling pathway | 3.09E-02 | 3 | P22694, Q13635, P10415 | PRKACB, PTCH1, BCL2 | More | |
| Aceclofenac | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | |
| Aceclofenac | hsa04610 | Complement and coagulation cascades | 2.33E-03 | 1 | P0C0L4 | C4A | More | |
| Aceclofenac | hsa04612 | Antigen processing and presentation | 3.90E-03 | 6 | P13765, P48382, P26715, P26717, Q13241, P01732 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, CD8A | More | |
| Aceclofenac | hsa04613 | Neutrophil extracellular trap formation | 3.77E-03 | 12 | O60603, P05164, P08246, Q9UM07, Q93077, P62807, O60814, P68431, Q15080, P20160, P08311, P21730 | TLR2, MPO, ELA2, PADI4, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF4, AZU1, CTSG, C5AR1 | More | |
| Aceclofenac | hsa04650 | Natural killer cell mediated cytotoxicity | 1.46E-04 | 9 | P01375, P06239, O60880, P20963, Q13241, P26718, O75015, P26717, P26715 | TNF, LCK, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KLRC1 | More | |
| Aceclofenac | hsa04657 | IL-17 signaling pathway | 4.87E-02 | 2 | P07900, P01584 | HSP90AA1, IL1B | More | |
| Aceclofenac | hsa04658 | Th1 and Th2 cell differentiation | 1.07E-03 | 7 | Q04759, P20963, P09693, Q14765, P23771, Q9UL17, P13765 | PRKCQ, CD247, CD3G, STAT4, GATA3, TBX21, HLA-DOB | More | |
| Aceclofenac | hsa04659 | Th17 cell differentiation | 1.90E-02 | 6 | Q04759, P13765, Q9UL17, P23771, P09693, P20963 | PRKCQ, HLA-DOB, TBX21, GATA3, CD3G, CD247 | More | |
| Aceclofenac | hsa04660 | T cell receptor signaling pathway | 8.92E-04 | 12 | P01375, Q9UDY8, Q04759, P10747, Q08881, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, MALT1, PRKCQ, CD28, ITK, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | |
| Aceclofenac | hsa04721 | Synaptic vesicle cycle | 3.09E-02 | 2 | Q99437, P43005 | ATP6V0B, SLC1A1 | More | |
| Aceclofenac | hsa04725 | Cholinergic synapse | 4.83E-02 | 4 | P22694, Q14643, P18848, P10415 | PRKACB, ITPR1, ATF4, BCL2 | More | |
| Aceclofenac | hsa04728 | Dopaminergic synapse | 2.82E-02 | 6 | P14416, P63218, P50151, P49841, Q16539, P49407 | DRD2, GNG5, GNG10, GSK3B, MAPK14, ARRB1 | More | |
| Aceclofenac | hsa04915 | Estrogen signaling pathway | 2.96E-02 | 5 | P14780, P22694, P18848, Q14643, P10415 | MMP9, PRKACB, ATF4, ITPR1, BCL2 | More | |
| Aceclofenac | hsa04918 | Thyroid hormone synthesis | 3.50E-02 | 3 | P22694, P18848, Q14643 | PRKACB, ATF4, ITPR1 | More | |
| Aceclofenac | hsa04922 | Glucagon signaling pathway | 4.23E-02 | 4 | P22694, P06737, Q12778, Q14643 | PRKACB, PYGL, FOXO1, ITPR1 | More | |
| Aceclofenac | hsa04924 | Renin secretion | 1.04E-02 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | |
| Aceclofenac | hsa04927 | Cortisol synthesis and secretion | 8.60E-03 | 3 | Q14643, P18848, P22694 | ITPR1, ATF4, PRKACB | More | |
| Aceclofenac | hsa04928 | Parathyroid hormone synthesis, secretion and action | 2.33E-03 | 5 | Q14643, P22694, P23771, P18848, P10415 | ITPR1, PRKACB, GATA3, ATF4, BCL2 | More | |
| Aceclofenac | hsa04932 | Non-alcoholic fatty liver disease | 9.70E-03 | 4 | P18848, P01584, P13073, O15239 | ATF4, IL1B, COX4I1, NDUFA1 | More | |
| Aceclofenac | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | |
| Aceclofenac | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | |
| Aceclofenac | hsa05012 | Parkinson disease | 2.53E-02 | 5 | O15239, P13073, P05141, P18848, Q13557 | NDUFA1, COX4I1, SLC25A5, ATF4, CAMK2D | More | |
| Aceclofenac | hsa05016 | Huntington disease | 3.21E-02 | 5 | O15239, P13073, P30876, P62487, P05141 | NDUFA1, COX4I1, POLR2B, POLR2G, SLC25A5 | More | |
| Aceclofenac | hsa05020 | Prion disease | 3.37E-03 | 7 | P13591, P01584, P11142, O15239, P13073, P18848, P05141 | NCAM1, IL1B, HSPA8, NDUFA1, COX4I1, ATF4, SLC25A5 | More | |
| Aceclofenac | hsa05022 | Pathways of neurodegeneration - multiple diseases | 3.80E-02 | 6 | O15239, P13073, P18848, P05141, P01584, Q13557 | NDUFA1, COX4I1, ATF4, SLC25A5, IL1B, CAMK2D | More | |
| Aceclofenac | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Aceclofenac | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.09E-03 | 6 | Q16539, Q99437, P10145, P25024, P25025, P07948 | MAPK14, ATP6V0B, IL8, CXCR1, CXCR2, LYN | More | |
| Aceclofenac | hsa05133 | Pertussis | 4.20E-02 | 1 | P0C0L4 | C4A | More | |
| Aceclofenac | hsa05134 | Legionellosis | 1.28E-02 | 3 | P01584, P68104, P11142 | IL1B, EEF1A1, HSPA8 | More | |
| Aceclofenac | hsa05135 | Yersinia infection | 4.65E-02 | 5 | P13612, P06239, Q16539, P01375, P49841 | ITGA4, LCK, MAPK14, TNF, GSK3B | More | |
| Aceclofenac | hsa05143 | African trypanosomiasis | 1.31E-02 | 2 | P69905, P68871 | HBA2, HBB | More | |
| Aceclofenac | hsa05144 | Malaria | 2.24E-03 | 6 | P60033, P69905, P68871, P01375, P35443, P26718 | CD81, HBA2, HBB, TNF, THBS4, KLRK1 | More | |
| Aceclofenac | hsa05162 | Measles | 4.02E-02 | 3 | P11142, P01584, Q9NP90 | HSPA8, IL1B, RAB9B | More | |
| Aceclofenac | hsa05163 | Human cytomegalovirus infection | 1.72E-02 | 8 | P01375, P63218, P50151, P49841, P14778, P25025, Q16539, O00463 | TNF, GNG5, GNG10, GSK3B, IL1R1, CXCR2, MAPK14, TRAF5 | More | |
| Aceclofenac | hsa05171 | Coronavirus disease - COVID-19 | 9.72E-03 | 7 | P01584, P62753, P25398, P36578, P32969, P18077, P62829 | IL1B, RPS6, RPS12, RPL4, RPL9, RPL35A, RPL23 | More | |
| Aceclofenac | hsa05202 | Transcriptional misregulation in cancer | 1.63E-03 | 12 | Q12778, Q15532, Q13315, P14780, Q15744, Q16548, O15550, P05164, P12838, P08246, Q9C0K0, P24522 | FOXO1, SS18, ATM, MMP9, CEBPE, BCL2A1, UTX, MPO, DEFA4, ELA2, BCL11B, GADD45A | More | |
| Aceclofenac | hsa05203 | Viral carcinogenesis | 6.22E-03 | 5 | Q12933, P42229, Q15283, P62807, O60814 | TRAF2, STAT5A, RASA2, HIST1H2BC, H2BC12 | More | |
| Aceclofenac | hsa05204 | Chemical carcinogenesis | 1.77E-04 | 4 | Q16772, P09211, P78417, P11712 | GSTA3, GSTP1, GSTO1, CYP2C9 | More | |
| Aceclofenac | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 2.84E-02 | 5 | P20963, P09693, O60603, P10747, Q04759 | CD247, CD3G, TLR2, CD28, PRKCQ | More | |
| Aceclofenac | hsa05321 | Inflammatory bowel disease | 8.69E-05 | 6 | O60603, P13765, Q14765, Q9UL17, P23771, Q9HBE5 | TLR2, HLA-DOB, STAT4, TBX21, GATA3, IL21R | More | |
| Aceclofenac | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Aceclofenac | hsa05323 | Rheumatoid arthritis | 1.60E-02 | 4 | P13765, P10747, P09341, O60603 | HLA-DOB, CD28, CXCL1, TLR2 | More | |
| Aceclofenac | hsa05332 | Graft-versus-host disease | 6.43E-05 | 4 | P13765, P10747, P26715, Q13241 | HLA-DOB, CD28, KLRC1, KLRD1 | More | |
| Aceclofenac | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | |
| Aceclofenac | hsa05415 | Diabetic cardiomyopathy | 2.87E-02 | 4 | P05141, O15239, P13073, Q13557 | SLC25A5, NDUFA1, COX4I1, CAMK2D | More | |
| Aceclofenac | hsa05418 | Fluid shear stress and atherosclerosis | 3.61E-02 | 6 | Q16539, P10599, P14780, P01375, P14778, P27930 | MAPK14, TXN, MMP9, TNF, IL1R1, IL1R2 | More | |
